Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Incyte Corporation

http://www.incyte.com

Latest From Incyte Corporation

England Rejects Funding For Kimmtrak, Onureg & Minjuvi But Says Yes To Idefirix, Evrenzo & Verzenios

Immunocore’s advanced uveal melanoma drug, Kimmtrak, and Hansa’s Idefirix for increasing the chances of a successful kidney transplant are among the latest treatments that NICE has appraised regarding their cost-effectiveness.

United Kingdom Cost Effectiveness

Keeping Track: US FDA Okays Alnylam’s siRNA Amvuttra, Alopecia Claim For Lilly’s Olumiant; Sierra Submits Momelotinib

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

SIFI’s Parasitic Eye Infection Drug & Biosimilar Aflibercept Among Raft Of EU Filings

Polyhexanide, from SIFI, could become the first approved treatment for acanthamoeba keratitis, while aflibercept could become the first biosimilar version of Eylea in the EU.

Europe Drug Review

As Its Debut Cancer Drug Struggles, MorphoSys Continues Refocus With $1bn Licensing Deal

The deal will help MorphoSys focus on lifting lackluster Monjuvi sales, and on bringing its promising myelofibrosis candidate pelabresib to market.

Companies Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Other Names / Subsidiaries
    • Maxia Pharmaceuticals, Inc.
UsernamePublicRestriction

Register